Exelixis (NASDAQ:EXEL) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Friday.
Other equities research analysts have also issued research reports about the company. Oppenheimer lowered their price objective on Exelixis from $30.00 to $29.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 2nd. Piper Sandler started coverage on Exelixis in a research report on Friday, November 19th. They issued an “overweight” rating and a $34.00 price objective on the stock. HC Wainwright lowered their price objective on Exelixis from $52.00 to $42.00 and set a “buy” rating on the stock in a research report on Friday. TheStreet lowered Exelixis from a “b-” rating to a “c” rating in a research report on Thursday, November 4th. Finally, Zacks Investment Research lowered Exelixis from a “buy” rating to a “sell” rating and set a $23.00 target price on the stock. in a research report on Monday, November 8th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Exelixis presently has a consensus rating of “Buy” and an average target price of $31.27.
Exelixis stock traded up $1.22 during mid-day trading on Friday, hitting $19.56. The company had a trading volume of 4,878,833 shares, compared to its average volume of 2,233,728. Exelixis has a 12-month low of $15.50 and a 12-month high of $25.77. The company’s fifty day moving average is $18.36 and its 200-day moving average is $18.95. The company has a market capitalization of $6.19 billion, a price-to-earnings ratio of 38.35, a P/E/G ratio of 0.58 and a beta of 0.86.
In other Exelixis news, EVP Peter Lamb sold 47,500 shares of the firm’s stock in a transaction on Wednesday, December 15th. The stock was sold at an average price of $17.44, for a total value of $828,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Patrick J. Haley sold 17,236 shares of the firm’s stock in a transaction on Wednesday, November 24th. The stock was sold at an average price of $17.25, for a total value of $297,321.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 124,736 shares of company stock valued at $2,200,321. 3.30% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of EXEL. Amundi Pioneer Asset Management Inc. increased its stake in shares of Exelixis by 182.1% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 176,193 shares of the biotechnology company’s stock worth $4,193,000 after acquiring an additional 113,733 shares during the last quarter. Advisory Services Network LLC purchased a new position in shares of Exelixis during the 2nd quarter worth $43,000. Stifel Financial Corp grew its holdings in shares of Exelixis by 3.1% during the 2nd quarter. Stifel Financial Corp now owns 134,567 shares of the biotechnology company’s stock worth $2,452,000 after purchasing an additional 4,053 shares during the period. LPL Financial LLC grew its holdings in shares of Exelixis by 95.9% during the 2nd quarter. LPL Financial LLC now owns 37,063 shares of the biotechnology company’s stock worth $675,000 after purchasing an additional 18,143 shares during the period. Finally, Allianz Asset Management GmbH purchased a new position in shares of Exelixis during the 2nd quarter worth $7,275,000. 82.80% of the stock is owned by institutional investors and hedge funds.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B.